FTSE 100 news / Companies and sectors / AstraZeneca / Myriad and SOPHiA partner with AstraZeneca on PrGIS

Myriad and SOPHiA partner with AstraZeneca on PrGIS

+5.0 positive

Myriad and SOPHiA Genetics teamed up with AstraZeneca on a prostate cancer genomic score.

3 headlines from 3 outlets, on 9 October 2026. The story's tone is the average of its headlines' own scores.

How each outlet covered it

Average tone of each outlet's headlines in this story. One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.

Outlet	Headlines	Tone
Dealroom	1	+5.0
GuruFocus	1	+5.0
Seeking Alpha	1	+5.0

Day by day

Friday 9 October 2026 3 headlines

Myriad and SOPHiA Genetics teamed up with AstraZeneca on a prostate cancer genomic score.

+5.0 Myriad, SOPHiA GENETICS and AstraZeneca team up on prostate cancer genomic score PrGIS Dealroom
Collaboration on prostate cancer genomic score with AstraZeneca
+5.0 Myriad Genetics (MYGN) Partners with AstraZeneca and SOPHiA Gene GuruFocus
Diagnostic partnership involving AstraZeneca in prostate cancer
+5.0 Myriad, SOPHiA partner with AstraZeneca to use prostate cancer technology Seeking Alpha
Partnership on prostate cancer technology

AstraZeneca: all news analysis · Sector · FTSE 100 news